2024-10-23 13:25:00
The biotechnology company Biointaxis, a spin off of the German Research Institute Trias i Pujol (IGTP) in Badalona (Barcelona), has obtained 2.17 million euros in public funding to promote the development of its innovative gene therapy against Friedreich’s ataxia, a neurodegenerative disease that affects mobility and personal autonomy seriously.
On the one hand, the Ministry of Science, Innovation and University granted Biointaxis 1.7 million euros through a tender for aid for public-private collaboration. The remaining 466,000 euros come from funding from the European Commission.
Biointaxis explains that it has obtained very promising results in preclinical tests on primates. Its gene therapy is the only one currently in development capable of accessing both the central nervous system and peripheral organs, including the heart, with the aim of slowing the progression of Friedreich’s ataxia and restoring patients’ motor skills, alleviating the symptoms.
With this financing Biointaxis will soon be able to start clinical trials. Likewise, the company keeps a financing round open through the Capital Cell platform to continue pursuing its project.
With the results recently obtained in preclinical animal studies, Biointaxis will soon initiate regulatory procedures with the European (EMA) and North American (FDA) agencies to request orphan drug designation and clinical phase authorization. The company plans to begin evaluating the gene therapy in clinical trials in patients with Friedreich’s ataxia in 2026.
#biotech #startup #Biointaxis #raises #million #Ministry #Science #European #Commission #Companies